Oligonucleotide Synthesis Market to Reach $8.6 Billion by 2035, Driven by Therapeutic Pipeline Expansion and CRISPR Adoption
核心洞察
The global oligonucleotide synthesis market was valued at USD 2.8 billion in 2025 and is projected to reach USD 8.6 billion by 2035, growing at a CAGR of 12.5%.
Thermo Fisher Scientific (搜索) leads the market with a 15.2% share, while the top five players collectively hold approximately 55% of total revenue.
The therapeutics application segment is expected to grow at the highest CAGR of 13.25%, fueled by over 100 active nucleic acid therapeutic clinical trials and 24 FDA-approved oligonucleotide drugs.
The global oligonucleotide synthesis market was valued at USD 2.8 billion in 2025 and is forecast to reach USD 8.6 billion by 2035, expanding at a compound annual growth rate (CAGR) of 12.5%, according to a comprehensive report published by Global Market Insights Inc. This growth trajectory reflects the structural expansion of oligonucleotide therapeutics pipelines, the broad integration of synthetic oligonucleotides across clinical and research workflows, and the accelerating commercialization of precision medicine and gene editing platforms.
North America accounted for the largest regional market share in 2025, underpinned by a well-developed pharmaceutical and biotechnology industry concentrated primarily in the United States and sustained NIH research funding. Asia Pacific is projected to be the fastest-growing region, driven by expanding research activity, government investment in biotechnology infrastructure, and rapid growth in the molecular diagnostics industry across China, India, Japan, and South Korea.
Market Leaders and Competitive Dynamics
Thermo Fisher Scientific (搜索) leads the oligonucleotide synthesis market with a 15.2% share, consolidated through an extensive product portfolio spanning research-grade through GMP-grade synthesis and a global manufacturing infrastructure. The top five players — Thermo Fisher Scientific, Eurofins (搜索), GenScript (搜索), Merck (搜索), and Agilent Technologies (搜索) — collectively held approximately 55% of total market revenue in 2025.
The competitive landscape has seen ongoing consolidation, with established players pursuing acquisitions of specialty synthesis providers to expand capability sets and geographic reach. In a Q4 2024 expert panel involving procurement leads at six major pharmaceutical companies, all six participants indicated that supplier qualification criteria had tightened materially over the preceding 24 months, with GMP certification, batch documentation quality, and supply chain resilience ranked ahead of price in overall vendor selection scoring.
Therapeutic Applications Drive Premium Growth
The therapeutics segment accounts for 38% of total application revenue and is projected to expand at the highest CAGR of 13.25% among all application categories. This segment is anchored by a growing pharmaceutical pipeline of antisense oligonucleotide drugs, siRNA therapeutics, RNA aptamers, and emerging RNA-based therapeutic formats targeting cancer, rare genetic disorders, cardiovascular diseases, and infectious conditions.
Regulatory agencies have cleared 24 oligonucleotide drugs targeting conditions spanning rare genetic disorders, liver diseases, neurological conditions, and cardiovascular risk. Drugs such as nusinersen for spinal muscular atrophy (搜索) and inclisiran for cardiovascular risk management have demonstrated the clinical and commercial viability of this therapeutic class. The broader pipeline includes over 100 active nucleic acid therapeutic clinical trials.
The FDA's 2024 Guidance for Oligonucleotide Drug Substance Manufacturing established expanded GMP quality standards for oligonucleotide active pharmaceutical ingredients, reinforcing compliance requirements for synthesis providers serving pharmaceutical customers. In a Q1 2025 survey covering 280 pharmaceutical procurement directors across North America and Europe, 68% indicated that GMP-grade oligonucleotide synthesis capacity represented one of their top three supply chain priorities for the current fiscal year, a marked increase from 41% observed two years prior.
CRISPR and Gene Editing Fuel New Demand
The widespread adoption of CRISPR-Cas systems across drug discovery, agriculture, and synthetic biology has created a structurally new and rapidly expanding demand category. Guide RNA synthesis, which requires precise sequence control and high-throughput production capacity, has become one of the fastest-growing service lines offered by commercial oligonucleotide manufacturers.
The approval of Casgevy (exagamglogene autotemcel) for sickle cell disease (搜索) and beta thalassemia (搜索) in late 2023 validated the clinical utility of CRISPR-Cas9 (搜索) technology and immediately expanded commercial demand for GMP-grade guide RNA synthesis. Supply chain leads interviewed across Tier 1 synthesis providers indicated that 60% of their academic and institutional customers had expanded oligonucleotide orders related to CRISPR functional screening by mid-2025, up from approximately 25% just 24 months earlier.
Companies including Integrated DNA Technologies (搜索) and Twist Bioscience (搜索) have developed dedicated CRISPR oligonucleotide product lines, including modified guide RNA formats, predesigned library pools, and custom synthesis services for both academic and pharmaceutical research customers.
High-Complexity Oligo Pools and Synthetic Biology
Rising demand for high-complexity oligo pools used in synthetic biology, CRISPR screening, and large-scale genomics projects represents a major structural trend. Twist Bioscience (搜索) has positioned itself at the intersection of computational biology and oligonucleotide manufacturing, offering a silicon-based DNA synthesis platform capable of producing complex oligo pools at costs significantly lower than conventional synthesis methods.
The equipment segment, representing 13.90% of the market, is projected to grow at the highest CAGR of 13.58% among all product type sub-segments, reflecting capital investment in automation and high-throughput synthesis platforms that underpin oligo pool production at scale.
Pharmaceutical Companies Dominate End-Use Demand
Pharmaceutical and biotechnology companies constitute the dominant end-use segment, representing 55% of total market revenue with a projected CAGR of 12.65%. These companies are increasingly establishing long-term supply agreements with GMP-qualified synthesis providers to ensure continuity of supply for oligonucleotide-based drugs in clinical trials.
Contract research organizations hold a 15.6% market share and are projected to grow at the highest end-use segment CAGR of 13.27%, driven by the sustained trend toward outsourcing drug discovery and preclinical testing activities. In a Q3 2024 survey covering 340 procurement and operations leads at CROs across North America, Europe, and Asia Pacific, 74% reported increasing their oligonucleotide procurement over the preceding 18 months, with CRISPR applications, NGS library preparation, and therapeutic candidate profiling identified as the primary demand drivers.
Recent Industry Developments
Several notable developments have shaped the market. In July 2025, Maravai LifeSciences announced the expansion of its GMP RNA and oligonucleotide synthesis capacity at its San Diego, California facility. In May 2025, Thermo Fisher Scientific (搜索) launched an expanded platform for GMP-grade oligonucleotide synthesis services. In January 2025, Astellas Pharma received FDA approval to remove dosing duration limits from IZERVAY (avacincaptad pegol), an oligonucleotide-based therapeutic for geographic atrophy (搜索). In November 2024, GenScript (搜索) completed the expansion of its oligonucleotide and gene synthesis operations in the Netherlands.
The market faces challenges including stringent regulatory requirements, high production costs, and biosafety and biosecurity concerns. However, the sustained demand across therapeutic, diagnostic, and research applications, combined with growing manufacturing investments by leading commercial synthesis providers, is expected to support double-digit growth across the forecast horizon.